Skip to content

Study · Non-randomized trial · 2024

2 results

Randomized controlled trial of linaclotide in children aged 6-17 years with functional constipation.

Di Lorenzo C, Nurko S, Hyams JS, Rodriguez-Araujo G, Almansa C, Shakhnovich V, Saps M, Simon M

Journal of pediatric gastroenterology and nutrition27 Mar 2024Cited by 8 (Europe PMC)

PMID38533633 (opens in a new tab)DOI10.1002/jpn3.12184 (opens in a new tab)PepBankPUB-38533633
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children aged 6-11 years with functional constipation, linaclotide 36 or 72 μg showed numerical SBM frequency improvement of 1.90.

    In plain wordsYounger children receiving linaclotide had a numerical improvement in bowel movement frequency compared with baseline.

    Peptide
    Linaclotide
    Outcome
    IncreaseSBM frequency, younger children
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Bowel Function · Gastrointestinal
    Studied dose
    36 or 72 μg once daily · 4 weeksAs given in this study (human).

    Measurements

    SBM frequency improvement
    1.9 per week
    6-11 years, 36 or 72 μg

    Source sentences

    Summary
    A numerical improvement in mean SBM frequency was observed with increasing linaclotide doses (1.90 in 6- to 11-year-olds [36 or 72 μg] and 2.86 in 12- to 17-year-olds [72 μg]).
    1 context sentence
    Summary · context
    This study evaluated the safety and efficacy of several linaclotide doses in children 6-17 years old with FC.
  2. 02HumanNon-randomized trialEfficacy outcome

    In children aged 12-17 years with functional constipation, linaclotide 72 μg showed numerical SBM frequency improvement of 2.86.

    In plain wordsOlder children receiving linaclotide had a numerical improvement in bowel movement frequency compared with baseline.

    Peptide
    Linaclotide
    Outcome
    IncreaseSBM frequency, older children
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Bowel Function · Gastrointestinal
    Studied dose
    72 μg once daily · 4 weeksAs given in this study (human).

    Measurements

    SBM frequency improvement
    2.86 per week
    12-17 years, 72 μg

    Source sentences

    Summary
    A numerical improvement in mean SBM frequency was observed with increasing linaclotide doses (1.90 in 6- to 11-year-olds [36 or 72 μg] and 2.86 in 12- to 17-year-olds [72 μg]).
    1 context sentence
    Summary · context
    This study evaluated the safety and efficacy of several linaclotide doses in children 6-17 years old with FC.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.